Does dextropropoxyphene and its salts qualify for India–UAE CEPA?

No — this line is currently excluded from India's CEPA tariff offer, so the preferential rate does not apply regardless of origin.

What proof is needed at import?

A preferential Certificate of Origin filed through eCoO 2.0, presented at customs before clearance. Without it, the 7.5% MFN duty applies.

Dextropropoxyphene and its salts (HS 29221400) under India–UAE CEPA

HS 29221400 · OXYGEN-FUNCTION AMINO-COMPOUNDS · Rules of Origin & preferential rate

Data last updated: 20 August 2026 · MFN duty & IGST verified against ICEGATE (Indian Customs EDI). Rules of Origin per CEPA Annex 3B. Verify your exact HS line before filing.

Import prohibited

Prohibited in India since 2013. The Ministry of Health and Family Welfare banned the manufacture, sale and distribution of dextropropoxyphene and its formulations on the advice of the Drugs Technical Advisory Board, citing cardiotoxicity and overdose risk. It appears on CDSCO's list of drugs prohibited for manufacture and sale in India, so no import route exists under CEPA or the MFN tariff. source ↗

CEPA eligible: Excluded
Value addition (RVC): 40%
Tariff-classification change: CTSH
MFN → CEPA basic duty: 7.5% → 7.5%

Rule of Origin (CEPA Annex 3B, primary source): CTSH + VA 40% (CEPA Annex 3B Product-Specific Rule; tariff-shift AND value addition both required).

Qualifying under the Rules of Origin

Dextropropoxyphene and its salts (HS 29221400) is currently excluded from India's India–UAE CEPA tariff offer, so no preferential rate applies regardless of origin. For reference, the Product-Specific Rule for this line is "CTSH + VA 40% (CEPA Annex 3B Product-Specific Rule; tariff-shift AND value addition both required).". Dextropropoxyphene is an opioid analgesic that India prohibited in 2013 after a review of cardiac-toxicity and overdose risk, following similar withdrawals in the United States and European Union. The tariff line survives in the schedule, and CEPA nominally lists it, but no duty rate is reachable: the drug cannot lawfully be imported, manufactured or sold in India in any formulation. Importers occasionally encounter it in legacy catalogues or combination-product offers from overseas suppliers. Treat any such offer as non-compliant regardless of price, origin or the availability of a Certificate of Origin. Because the line is excluded, customs charges the 7.5% MFN rate. Confirm eligibility against India's CEPA tariff schedule before assuming any benefit.

Check your own figures in the Rules of Origin (RVC) qualifier.

Frequently asked questions

Does dextropropoxyphene and its salts qualify for India–UAE CEPA?: No — this line is currently excluded from India's CEPA tariff offer, so the preferential rate does not apply regardless of origin.
What is the Rule of Origin for dextropropoxyphene and its salts?: Per CEPA Annex 3B: CTSH + VA 40% (CEPA Annex 3B Product-Specific Rule; tariff-shift AND value addition both required).. RVC% = [(FOB − value of non-originating materials) / FOB] × 100 (FOB basis).
What proof is needed at import?: A preferential Certificate of Origin filed through eCoO 2.0, presented at customs before clearance. Without it, the 7.5% MFN duty applies.